DiaKine Therapeutics, Inc.
http://http://www.diakine.com/default.htm
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DiaKine Therapeutics, Inc.
Keeping Track: First-In-Class Candidates In COPD, Cancer Join US FDA Review Queue
Recent applications for approval also include another DMD therapy, another hemophilia B gene therapy, and a new antibiotic.
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
Beta/Islet Cell Regeneration Leads Diabetes Deal-Making This Decade
A review of deal-making in the diabetes space since 2010 finds deals around technology to regenerate pancreatic beta cells and/or islet cells as the hottest mechanism of action. Thirteen deals in this area out-number the combined deals involving the DPP-4, SGLT-2 and GLP-1 mechanisms during that period.
Deals Shaping The Medical Industry, April 2012
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice